Skip to content
Fibrosis Icon

Respiratory, Cardiometabolic & Renal

Fibroproliferative and cardiometabolic disorders are estimated to contribute to 45% of deaths*. The magnitude of this unmet clinical need is resulting in intense efforts to develop novel therapeutics.


The Respiratory, Cardiometabolic & Renal Event Series' mission is to enable drug developers to eradicate these types of diseases and provide a better standard of care for patients.